Heron Therapeutics (HRTX) Cash & Current Investments (2010 - 2026)

Heron Therapeutics has reported Cash & Current Investments for 17 years, with the latest figure at $30.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 15.85% year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (down 15.85% YoY), and the FY2025 full-year result was $29.6 million, down 16.38% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $30.0 million, up from $29.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $121.7 million in Q3 2022, with the low at $29.3 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $52.4 million across 5 years, with a median of $40.6 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 84.78% — and 2024, when it soared 102.58%.
• Heron Therapeutics' Cash & Current Investments stood at $71.0 million in 2022, then fell by 19.66% to $57.0 million in 2023, then plunged by 37.96% to $35.4 million in 2024, then retreated by 16.38% to $29.6 million in 2025, then grew by 1.29% to $30.0 million in 2026.
• The last three Cash & Current Investments figures came in at $30.0 million (Q1 2026), $29.6 million (Q4 2025), and $29.3 million (Q3 2025), per Business Quant data.